Intervention1: Capecitabine: 1250 mg/m2 administered twice daily orally :BD (morning and evening
Sponsors
Sun Pharmaceutical Industries Ltd
Conditions
Health Condition 1: null- Cancer
Unknown Phase
The study will be conducted to monitor safety and compare the bioavailability of Capecitabine 500 mg tablets of Sun Pharmaceutical Industries Limited, India, and Xeloda (Capecitabine) 500 mg of Roche Registration Ltd. after administration of single dose, in Cancer patients under fed conditions.
Active, not recruitingCTRI/2011/10/002090
Target: 44Updated: 2021-11-24
The study will be conducted to monitor safety and compare the bioavailability of Capecitabine 500 mg tablets of Sun Pharmaceutical Industries Ltd., India, and Xeloda (Capecitabine) 500 mg of Roche Registration Ltd., after administration of single dose, in Cancer patients under fed conditions.
Active, not recruitingCTRI/2011/12/002288
Target: 54Updated: 2021-11-24